Aceclidine ophthalmic solution
Sponsors
LENZ Therapeutics, Inc, Corxel Pharmaceuticals
Conditions
Eye DiseasesMiosisNear VisionPresbyopiaRefractive ErrorRefractive Errors
Phase 2
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
CompletedNCT05294328
Start: 2022-05-05End: 2022-09-10Updated: 2024-09-05
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
CompletedNCT05431543
Start: 2022-08-06End: 2022-12-14Updated: 2024-09-05
Phase 3
Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
CompletedNCT05656027
Start: 2022-12-19End: 2024-01-25Updated: 2026-02-25
Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
CompletedNCT05728944
Start: 2023-03-06End: 2024-01-24Updated: 2026-02-25
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
CompletedNCT05753189
Start: 2023-02-21End: 2024-02-09Updated: 2024-12-18
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
CompletedNCT06045299
Start: 2023-09-27End: 2025-01-27Updated: 2025-03-03